In conclusion, our results suggest that CSF SNAP-25 is a viable alternative to established diagnostic CSF surrogate biomarkers such as t-tau, 14–3-3, and the t-tau/p-tau ratio in discriminating CJD among RPD cases, especially from those of non-neurodegenerative etiology. This evidence concerns the gene MAPT and Creutzfeldt Jacob disease.